Hepatocyte growth factor suppresses melanogenesis via ERK-dependent nuclear exclusion of MITF Authors: Jeong Hyeon Lee, Jae Min Yoo, Youngsup Song, Sung Eun Chang Published: 2026 ABSTRACT AbstractBackgroundHepatocyte growth factor (HGF) has been considered a promising candidate for improving skin and hair quality. Solar lentigines—the most common UV-associated hyperpigmentary skin disorder—have historically been thought to involve HGF in their pathogenesis. However, the precise role of HGF in cutaneous melanogenesis remains unclear, and direct experimental evidence supporting its melanogenic function is lacking. This study aimed to systematically investigate the effects of HGF on melanogenesis and to elucidate the underlying molecular mechanisms.ResultHGF is predominantly expressed in dermal fibroblasts, whereas its receptor c-Met is highly expressed in melanocytes, particularly in human melanocytes. Unexpectedly, HGF significantly suppressed melanin production in mouse and human melanocytes, while promoting the survival and proliferation of human melanocytes. Mechanistically, HGF downregulated the expression of melanogenic enzymes, tyrosinase, Tyrp1, and DCT, without altering MITF expression. Instead, HGF activated ERK signaling, which inhibited nuclear translocation of MITF, thereby suppressing melanogenic gene expression. Consistent with in vitro findings, topical application of HGF significantly reduced epidermal melanin accumulation in KRT14-SCF transgenic mice and attenuated UVB-induced pigmentation in ex vivo cultured human skin.ConclusionsThese findings overturn the prevailing view of HGF as a melanogenic factor and identify HGF as a negative regulator of melanogenesis. Given its pro-survival effects on melanocytes, HGF may represent a promising preventive topical strategy for photoaging-associated hyperpigmentation without increasing the risk undesired melanocyte loss.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13578-026-01611-1.Keywords: hepatocyte growth factor, melanogenesis suppression, HGF–cMET pathway, ERK, MITF Background Skin hyperpigmentation is a frequent clinical finding associated with aging and photoaging, and it remains a significant therapeutic challenge in both dermatology and aesthetic medicine [1, 2]. Hyperpigmentation arises from excessive melanin synthesis and/or uneven melanin distribution within the epidermis and dermis. The most common etiologies include ultraviolet (UV) exposure and inflammatory processes, which can result in post-inflammatory hyperpigmentation (PIH). PIH develops following cutaneous inflammatory insults, such as acne, eczema, or procedure-induced injury, and is often exacerbated by subsequent UV exposure, which stimulates melanogenesis and contributes to both PIH and age-related dyschromia [3–7]. Traditionally regarded as a passive physical barrier against external insults, the skin is now recognized as an active and highly integrated neuro-immuno-endocrine organ. The skin contains a local hypothalamus–pituitary–adrenal (HPA) and hypothalamus-pituitary-thyroid (HPT)-like system capable of synthesizing and secreting diverse neuropeptides, hormones, cytokines, and stress mediators. Through this complex network, the skin dynamically senses environmental stressors and coordinates local homeostatic responses [8]. Among these environmental stimuli, ultraviolet radiation (UVR) is a primary regulator of cutaneous physiology and profoundly impacts the local skin microenvironment by inducing neuroendocrine and immune responses [9]. Within this integrated network, melanocyte function and melanogenesis are tightly regulated through crosstalk among classical hormones, locally produced neuropeptides, cytokines, and paracrine growth factors [10–12]. Although multiple stimulatory pathways regulating melanogenesis have been extensively characterized, inhibitory regulatory mechanisms mediated by locally derived factors remain incompletely understood in the context of UVR- and neuroendocrine-driven pigmentation responses. Hepatocyte growth factor (HGF), originally identified as a potent mitogen for hepatocytes, is a multifunctional cytokine that plays essential roles in diverse biological processes, including cellular proliferation, differentiation, motility, and survival [13]. HGF exerts its effects by binding to its cognate tyrosinase kinase receptor, c-Met, thereby activating multiple downstream signaling pathways, including MAPK/ERK, PI3K/AKT, and STAT3 [14, 15]. These signaling cascades orchestrate a broad range of cellular responses involved in tissue regeneration, wound healing, organ development, and inflammation regulation, reflecting the pleiotropic effects of HGF [16–18]. Given its long-standing perception as a melanogenic factor, we focused on investigating the direct role of HGF in melanocytes. Although HGF has been suggested to be involved in age-related skin pigmentation, including solar lentigines [19–22], to our knowledge its precise role in pigmentation has not been directly investigated and the underlying molecular mechanisms remain largely undefined. In this study, utilizing in vitro cultured cell systems, an ex vivo human skin model and in vivo epidermis-humanized mice, we explored the effects of HGF in melanogenesis and its potential application in the treatment of photoaging and inflammation-related hyperpigmentation disorders. Methods Chemicals and cell culture reagents Hepatocyte growth factor (HGF), forskolin (FSK), kojic acid, L-3,4-dihydroxyphenylalanine (L-Dopa), cholera toxin (CT), and 12-O-tetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). SCH772984, PD98059 and rottlerin were purchased from MCE (MedChemExpress, Monmouth Junction, NJ, USA) and prepared as a solution in DMSO. Dulbecco’s Modified Eagle Medium (DMEM), Dulbecco’s phosphate-buffered saline (DPBS), and fetal bovine serum (FBS) were purchased from WELGENE (Kyungsan, Kyungsangbook-do, Republic of Korea). Medium 254, EpiLifeTM Medium, Human Melanocyte Growth Supplement (HMGS), Human Keratinocyte Growth Supplement (HKGS), Antibiotic-Antimycotic (AA), and trypsin-EDTA were purchased from Gibco (Grand Island, NY, USA). Cell culture Mel-Ab cells, spontaneously immortalized melanocytes, were cultured in DMEM supplemented with 10% FBS, 100 nM TPA, and 1% AA. B16F10 mouse melanoma cells, A375 human melanoma cells, primary mouse fibroblasts, and human dermal fibroblast cells (HDF) were cultured in DMEM medium containing 10% FBS and 1% AA. Normal human primary melanocytes (NHM, Invitrogen Carlsbad, CA, USA), primary mouse melanocytes, and primary human melanocytes were cultured in Medium 254 supplemented with HMGS. Normal Human epidermal keratinocytes (NHK, Gibco) were cultured in EpiLifeTM Medium supplemented with HKGS and 1% AA. All cells were maintained at 37 °C in a humidified environment with 5% CO2. Cell viability and counting assay Cell viability was assessed using thiazolyl blue tetrazolium bromide (MTT; Duchefa, Netherlands). After 72 h of HGF treatment, cells were washed with phosphate-buffered saline (PBS) and incubated with 0.2 mg/mL MTT solution in PBS at 37 °C for 1 h in a humidified atmosphere containing 5% CO2. The resulting formazan crystals were dissolved in 1 mL of dimethyl sulfoxide (DMSO), and absorbance was measured at 565 nm using a microplate reader (BioTek, Winooski, VT, USA). Cell viability was expressed as a percentage of that of untreated control cells. For cell counting, NHM cells were seeded in 12-well plates and treated with HGF (20 ng/mL) for 24–72 h. Cells were harvested and the number of cells per well was determined at the indicated time. Melanin content assay Mel-Ab, B16F10, and NHM cells were treated with HGF (10–20 ng/mL) alone or pretreated with HGF for 1 h followed by stimulation with 10 µM FSK and cultured for an additional 72 h. Cells were then dissolved in 550 µL of 1 N NaOH and heated at 95 °C for 30 min to solubilize melanin. For mouse tissue samples, skin fragments were incubated in 350 µL of 1 N NaOH, mechanically disrupted using sterilized scissors, and heated at 95 °C for 3 h with intermittent vortexing. After centrifugation, the absorbance of the supernatant was measured at 405 nm using a microplate reader. Protein concentrations were determined using a Bradford assay and used for normalization. Intracellular melanin content was expressed as a percentage of that in control cells. Tyrosinase activity assay Intracellular tyrosinase activity was assessed by measuring the rate of dopachrome formation from L-DOPA. Mel-Ab cells were treated with HGF (1–20 ng/mL) or 200 µM kojic acid and incubated for 72 h, after which they were washed with ice-cold 1× phosphate-buffered saline (PBS). Cells were harvested using tyrosinase lysis buffer (phosphate buffer, pH 6.8, containing 1% Triton X-100) and lysed by 10 freeze–thaw cycles. Protein concentrations in the lysates were determined using a Bradford assay and normalized prior to analysis. For cell-free tyrosinase activity assays, mushroom tyrosinase (5 nM) was used in place of cell lysates according to the the manufacturer’s instruction (Sigma-Aldrich). 1–20 ng/mL of HGF or 200 µM kojic acid, a direct tyrosinase inhibitor, was added as the indicated concentrations. The reaction mixtures were pre-incubated at 37 °C for 6 h. Subsequently, 90 µL of each sample was mixed with 10 µL of 10 mM L-DOPA prepared in tyrosinase lysis buffer and incubated at 37 °C. Dopachrome formation was monitored by measuring absorbance at 475 nm at 10-min intervals for up to 1 h using a microplate reader. Western blot analysis For western blot analysis, adherent cells were pretreated with HGF (20 ng/mL) for 1 h, followed by treatment with PD98059 (10 µM), SCH772984 (1 µM), PHA-665,752 (1 µM; MCE), or FSK (10 µM) as indicated. Cells were washed with ice-cold 1× phosphate-buffered saline (PBS) and lysed in 100 µL of 1% SDS lysis buffer (100 mM Tris-HCl, 5 mM EDTA, 1% SDS, pH 7.4). Protein extracts from cultured cells or mouse and human ex vivo skin tissues were mixed with 5× sample buffer (25 µL) and boiled at 100 °C for 10–30 min. Proteins were separated by SDS–polyacrylamide gel electrophoresis on 6–12% gels and transferred onto nitrocellulose membranes (0.2 μm pore size; ATTO, Tokyo, Japan). Membranes were washed five times for 8 min each with 1× TBS-T buffer (20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 0.1% Tween-20) and blocked with 5% bovine serum albumin (BSA, Bovogen Biologicals, Keilor East, Australia) in TBS-T. Membranes were then immunoblotted with the indicated primary antibodies. Antibodies against tyrosinase, Tyrp1, DCT, and Lamin B1 were purchased from Abcam (Cambridge, UK). Antibodies against MITF, ERK, phospho-ERK, CRTC3, AKT, phospho-AKT, AMPK, phospho-AMPK, CREB, and phospho-CREB were obtained from Cell Signaling Technology (Danvers, MA, USA) and used at a dilution of 1:1000. An antibody against HSP90 was purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and used at a dilution of 1:2000. Cell fractionation For cell fractionation experiments, Mel-Ab cells were treated with HGF (20 ng/mL) for 1 h in the presence or absence of FSK. Nuclear and cytoplasmic fractions were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. CREB transcriptional activity assay CREB transcriptional activity was assessed using a promoter-based reporter assay with CRTC3/CREB reporter cell lines, as previously described [23]. Cells were treated with 20 ng/mL of HGF and/or 10 µM FSK as indicated. After 6 h of treatment, fly luciferase activity was measured according to the previously described protocol [24]. Rottlerin (1 µM) was used as a positive inhibitor of CREB activity [25]. Transcriptional activity of CREB was expressed as a percentage relative to that of vehicle-treated control cells. mRNA expression analysis Total RNA was extracted from all cell types under the conditions indicated in in the figures using the FavorPrepTM Total RNA Purification Mini Kit (Favorgen Biotech, Ping-Tung, Taiwan) according to the manufacturer’s instructions. Single-stranded complementary DNA (cDNA) was synthesized from 1 µg of total RNA using the RevertAid First-Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instructions. Quantitative real-time PCR (qRT-PCR) was performed using Fast SYBRTM Green Master Mix (Toyobo, Osaka, Japan) with LightCycler 480 Multiwell Plate 96 White (Roche Life Science, Penzberg, Germany) on a LightCycler 480 Instrument II (Roche Applied Science, Indianapolis, IN, USA). GAPDH was used as an internal reference and the primer sequences used for qRT-PCR are listed below. NameForwardReversemGAPDH5’-CATCACTGCCACCCAGAAGACTG-3’5’-ATGCCAGTGAGTTCCCGTTCAG-3’hGAPDH5’-GTCTCCTCTGACTTCAACAGCG-3’5’-ACCACCCTGTTGCTGTAGCCAA-3’mHGF5’- GCAGTACCCTCACAAGCATG-3’5’- ACTCGGATGTTTGGGTCAGT-3’hHGF5’- TGGTAAAGGACGCAGCTACA-3’5’- GCGTACCTCTGGATTGCTTG-3’mC-Met5’- AGTCTGTGCATTCCCCATCA-3’5’- GAGTTTCTCAGCAGGGTCCT-3’hC-Met5’-CCCACCCTTTGTTCAGTGTG-3’5’-AGTCAAGGTGCAGCTCTCAT-3’mMITF5’-TGAAGCAAGAGCATTGGCTA-3’5’-TCCACAGAGGCCTTGAGAAT-3’mTyrosinase5’-TTATGCGATGGAACACCTGA-3’5’-ACTGGCAAATCCTTCCAGTG-3’mTyrp15’-TCACTGATGCGGTCTTTGAC-3’5’-CTGACCTGGCCATTGAACTT-3’mDCT5’-TCCTAACCGCAGAGCAACTT-3’5’-TCTCCATTAAGGGCGCATAG-3’ Animal experiments and histological analysis C57BL/6J mice carrying the KRT14-stem cell factor (SCF) transgene (KRT14-SCF) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and bred with C57BL/6J mice. Resulting KRT14-SCF+/− mice were used for all experiments, as previously described [26]. For topical application, HGF was prepared at a concentration of 100 ng/mL in a topical carrier consisting of 70% ethanol and 30% propylene glycol. A total volume of 100 µL of vehicle alone or HGF-containing solution was applied evenly to the tails and ears of KRT14-SCF+/− mice every two days. After 50 days of treatment, skin tissues were harvested from vehicle- or HGF-treated mice and immediately fixed for paraffin embedding. Ex-vivo human skin culture experiments Skin samples were washed with 70–100% ethanol and placed in a Petri dish containing PBS. The skin tissues were cut into 2 cm2 pieces and placed in transwell inserts with the epidermal side facing up and exposed to air. Explants were cultured at 37 °C in a humidified atmosphere with 5% CO2. The culture medium consisted of DMEM supplemented with 10% FBS and 10% AA was replaced daily. To induce UVB-stimulated melanin production, skin explants were irradiated with 200 mJ/cm2 of UVB for 30 s followed by topical application topical carrier containing either vehicle or 50–100 ng/mL HGF every 48 h for 96 h. Skin tissue were harvested and one portion was fixed in 10% formalin and embedded in paraffin for histological analysis and the remaining portion was snap-frozen, pulverized, lysed and analyzed by western blotting. Fontana-Masson staining and histological analysis Paraffin-embedded mouse tails and ears skin tissue was cut into 6-µm-thick sections and stained using a Fontana-Masson kit (ID Labs, London, ON, Canada) in combination with hematoxylin and eosin (H&E) staining according to the manufacturer’s instructions. The melanin index was determined by measuring the percentage of stained area relative to the total tissue area using ImageJ software (version 1.53 K, National Institutes of Health, USA) as described previously [27]. Statistical analysis Data are expressed as mean ± SEM, and statistical significance was determined by t-test using the GraphPad Prism program. In this study, P < 0.05, P < 0.01, and P < 0.001 were considered statistically significant and were denoted by *, ** and *** respectively. . Results The expression pattern of HGF and HGF receptor in skin cells To investigate the function of HGF in skin tissue, we first examined the mRNA expression levels of HGF and its receptor, c-Met, in key cutaneous cell types using qRT-PCR. HGF mRNA expression was predominantly higher in dermal fibroblasts compared to melanocytes and keratinocytes in both mouse and human samples (Fig. 1a, b). In contrast, c-Met mRNA expression was relatively evenly distributed among mouse melanocytes, and dermal fibroblasts, whereas its levels in human cells were significantly higher in melanocytes than in dermal fibroblasts and keratinocytes (Fig. 1c, d). This complementary expression pattern of HGF and c-Met suggests a paracrine mode of action in the skin, whereby fibroblast-derived HGF may act on epidermal melanocytes. Notably, c-Met expression levels were higher in melanoma cell lines compared to those in normal melanocytes (Fig. 1c, d). The relative expression levels of HGF and MET in melanocytes, keratinocytes, and dermal fibroblasts. The relative mRNA levels of (a, b) HGF and (c, d) MET (c-Met) were assessed by real-time qRT-PCR in primary cultured dermal melanocyte from C57BL/6J mice, Mel-Ab (spontaneously immortalized mouse melanocytes), B16F10 mouse malanoma cell, primary mouse fibroblast, primary cultured melanocytes, normal human melanocytes (NHM), normal human keratinocytes (NHK), human dermal fibroblasts (HDF), and A375 human melanoma cells HGF suppresses melanin production HGF is well recognized for its role in melanocyte growth, proliferation, and survival. Although HGF has been regarded as a melanogenic factor, direct experimental evidence supporting this role remains lacking, with most studies relying on indirect observations or correlational clinical data. To investigate the direct role of HGF in melanogenesis, we first evaluated its effects on cell viability in cultured melanocyte and melanoma cell lines. HGF treatment at concentrations up to 50 ng/mL did not affect cell viability or induce cytotoxicity in either B16F10 melanoma cells or Mel-Ab melanocytes (Fig. 2a, b). Effects of HGF on cell viability and melanin production in mouse and human melanocytes. a B16F10 melanoma cells and b. Mel-Ab melanocytes were treated with the indicated concentrations of HGF, and cell viability was assessed by MTT assay. Melanin content in c. B16F10 and d. Mel-Ab cells under basal and FSK-stimulated conditions following HGF treatment. e MTT assay of primary normal human melanocytes (NHM) treated with HGF. f Changes in actual cell numbers of NHM at the indicated time points following HGF treatment. g Melanin content in primary normal human melanocytes treated with increasing concentrations of HGF for 72 h Next, the effects of HGF on melanin production were evaluated. In B16F10 cells, contrary to previous assumptions, HGF treatment reduced melanin content under both basal and FSK-stimulated conditions (Fig. 2c). Similarly, in Mel-Ab melanocytes, HGF significantly suppressed melanin production under basal conditions as well as in response to FSK stimulation (Fig. 2d and Fig S1). The effects of HGF were further examined in primary normal human melanocytes (NHM). In contrast to mouse melanocytes and melanoma cells, HGF treatment dose-dependently increased cell viability in NHM (Fig. 2e). Consistent with this finding, direct cell counting also showed a significant increase in cell numbers in HGF-treated NHM over time (Fig. 2f), indicating that HGF enhances the survival and/or proliferation of primary human melanocytes. Notably, in contrast to previous assumptions but consistent with the inhibitory effects observed in mouse melanocytes (Fig. 2c, d), HGF treatment led to a dose-dependent reduction in melanin levels after 72 h of treatment (Fig. 2g). HGF downregulates melanogenic gene expression independently of MITF levels To investigate the mechanisms underlying HGF-mediated suppression of melanogenesis, we first examined its effects on tyrosinase activity, a rate-limiting enzyme in melanin synthesis. Reflecting the observed inhibitory effects of HGF on melanogenesis, cellular tyrosinase activity was significantly reduced in Mel-Ab cells treated with HGF for 72 h (Fig. 3a). In contrast, HGF did not inhibit tyrosinase catalytic activity when assessed using an in vitro tyrosinase assay (Fig. 3b), indicating that HGF is not a direct inhibitor of tyrosinase. Effects of HGF on tyrosinase activity and melanogenesis-related gene expression. a Cellular tyrosinase activity in Mel-Ab melanocytes treated with HGF for 72 h. b In vitro mushroom tyrosinase activity assay in the presence of HGF. Kojic acid was used as a positive control for direct inhibitor of tyrosinase. c Western blot and d. qRT-PCR analysis of melanogenesis-related gene expression in Mel-Ab melanocytes treated with HGF under basal and FSK-stimulated conditions for 48 and 72 h. e qRT-PCR analysis of melanogenesis-related gene expression in Mel-Ab melanocytes treated with HGF and FSK for short time periods (1–6 h) We next examined whether the reduction in cellular tyrosinase activity resulted from downregulation of tyrosinase expression. Treatment of Mel-Ab cells with HGF for 24–72 h suppressed both protein (Fig. 3c) and mRNA (Fig. 3d) expression levels of melanin biosynthesis–related genes, including tyrosinase, Tyrp1, and DCT, under both basal and FSK-stimulated conditions. To determine whether HGF affects the early transcriptional regulation of melanogenic genes, Mel-Ab cells were treated with HGF and FSK for short time periods (1–6 h). Under these conditions, HGF did not alter the mRNA expression levels of melanogenesis-related genes during the 1–6 h treatment period (Fig. 3e), suggesting that HGF-mediated suppression of melanin biosynthesis–related gene expression does not involve immediate transcriptional repression. Notably, in contrast to tyrosinase, Tyrp1, and DCT, the protein and mRNA levels of microphthalmia-associated transcription factor (MITF), a key transcriptional regulator of melanogenic gene expression, including tyrosinase, Tyrp1, and DCT, were not altered by HGF treatment (Fig. 3c, d). HGF-induces nuclear exclusion of MITF via ERK To elucidate the molecular mechanisms by which HGF regulates melanogenesis, we first examined the involvement of the CRTC3/CREB signaling axis. It is well established that AMP-activated protein kinase (AMPK)–mediated phosphorylation of CRTC3 promotes its nuclear export, thereby suppressing CRTC3/CREB-dependent transcription and subsequently reducing MITF and tyrosinase expression in melanocytes [23, 25, 26, 28]. HGF treatment increased the phosphorylation of CRTC3, whereas phosphorylation of AMPK, the active form of AMPK, remained unchanged (Fig. 4a). Moreover, consistent with the lack of change in MITF expression, HGF did not significantly alter CREB transcriptional activity, as assessed by a CREB reporter assay (Fig. 4b). HGF-mediated suppression of melanogenesis through ERK-dependent regulation of MITF nuclear localization. a Western blot analysis of phosphorylated and total CRTC3, CREB, and AMPK in Mel-Ab melanocytes treated with HGF. b CREB transcriptional activity assessed by CREB reporter assay following treatment with FSK alone or HGF and FSK. 1 µM Rottlerin was used as a negative control for CREB activation. c Western blot analysis of ERK and AKT phosphorylation in Mel-Ab melanocytes treated with HGF in the presence or absence of ERK inhibitors (SCH772984 and PD98059). d Effects of ERK inhibition on HGF-mediated suppression of melanin production. Mel-Ab cells were pretreated with an ERK inhibitors 30 min prior to HGF exposure. e Analysis of MITF protein expression and subcellular localization in Mel-Ab melanocytes treated with FSK and/or HGF Given that HGF activates c-Met downstream signaling pathways and induced phosphorylation of both CRTC3 and CREB [29, 30], we next focused on the ERK signaling pathway. HGF treatment markedly increased the phosphorylation of ERK and AKT in Mel-Ab cells, and this activation was attenuated by pretreatment with an ERK inhibitor (Fig. 4c). To assess the functional relevance of ERK activation in HGF-mediated suppression of melanogenesis, Mel-Ab cells were pretreated with an ERK inhibitor for 30 min prior to HGF exposure, and melanin content was measured after 72 h. Inhibition of ERK signaling effectively reversed the suppressive effect of HGF on melanin production (Fig. 4d and Fig S2), indicating that ERK activation is required for HGF-induced inhibition of melanogenesis. ERK is known to phosphorylate MITF at serine 73, leading to its nuclear export [31]. To test whether this mechanism contributes to HGF-mediated regulation of melanogenesis, we examined the effects of HGF on MITF expression and subcellular localization. While FSK treatment increased total MITF levels and promoted its nuclear accumulation, HGF treatment did not alter overall MITF protein levels but significantly inhibited FSK-induced nuclear translocation of MITF (Fig. 4e). These findings suggest that HGF suppresses melanogenesis primarily by impairing MITF nuclear localization rather than by reducing its expression. HGF reduces epidermal melanin accumulation in KRT14-SCF transgenic mice and in ex vivo cultured human skin To determine whether HGF modulates epidermal melanogenesis in vivo, HGF was topically applied to the dorsal skin and ears of KRT14-SCF transgenic mice, a model in which melanocytes are retained within the epidermis, for 50 days [27, 32]. H&E combined with Fontana-Masson staining revealed marked epidermal pigmentation in untreated transgenic mice, characterized by dense melanin deposition in the basal and suprabasal layers. In contrast, HGF-treated skin exhibited visibly reduced pigmentation without overt disruption of epidermal architecture or evidence of inflammatory infiltration (Fig. 5a). Biochemical quantification of melanin content using the NaOH lysis method confirmed a significant decrease in total melanin levels in HGF-treated dorsal and auricular skin compared with vehicle-treated controls (Fig. 5b). Consistently, the melanin index, determined by histomorphometric analysis, was also significantly reduced in HGF-treated skin tissues (Fig. 5c). HGF suppresses epidermal melanogenesis in KRT14-SCF transgenic mice in vivo. a Representative combined H&E and Fontana-Masson-stained sections of dorsal and ear skin from KRT14-SCF transgenic mice treated topically with vehicle or HGF for 50 days. HGF-treated skin shows reduced melanin deposition in the epidermis compared with controls. Scale bars, 20 μm. b Quantification of melanin content in skin tissues following NaOH lysis. c Melanin index measured from histological sections. HGF treatment significantly reduced epidermal pigmentation Finally, to further confirm HGF-mediated suppression of melanin accumulation in human skin, we employed an ex vivo human skin model. UVB exposure markedly induced epidermal melanin accumulation in human skin tissues, which was significantly attenuated by topical HGF treatment for 5 days (Fig. 6a, b). Consistent with data from cultured cell models, UVB increased both MITF and tyrosinase expression, whereas HGF treatment suppressed UVB-induced tyrosinase protein expression without altering MITF protein levels (Fig. 6c). HGF directly inhibits melanogenesis ex vivo and reduces tyrosinase protein level in human skin. a Representative combined H&E and Fontana-Masson staining of ex vivo human abdominal skin treated with UVB and vehicle or HGF for 5 days. Reduced epidermal melanin deposition is observed in HGF-treated samples. Scale bars, 20 μm. b Melanin index analysis showing decreased pigmentation by topical HGF treatment in human skin tissues. c Western blot analysis of MITF and tyrosinase protein levels in ex vivo human skin treated with UVB and vehicle or HGF. HSP90 was used as an internal loading control Upon UV exposure, keratinocyte-derived α-MSH activates melanocortin 1 receptor (MC1R) in melanocytes [12], leading to cAMP production, PKA activation, nuclear translocation of CRTC3, and CREB phosphorylation, which induce MITF expression and melanogenesis. In contrast, HGF secreted from dermal fibroblasts binds to its receptor c-MET and activates ERK signaling, promoting nuclear export and suppression of MITF transcriptional activity, thereby suppressing melanogenic gene expression and melanin synthesis. Discussion Cutaneous responses to UVR are coordinated by an integrated neuro-immuno-endocrine system that protects the skin against environmental stressors. This epidermal protective network comprises keratinocytes as well as pigmentary, neural, immune, and endocrine components that communicate through complex neurohormonal mediators and cytokine signaling pathways. For instance, UVR exposure activates a cutaneous HPA-like axis, leading to the production of proopiomelanocortin (POMC)-derived peptides such as α-melanocyte-stimulating hormone (α-MSH), together with various sensory neuropeptides and inflammatory mediators that promote pigmentation and protect against UVR-induced skin damage [9, 33, 34]. Dysregulation of these interconnected signaling pathways contributes to pigmentary disorders, including vitiligo, melasma, and pathological hypo- or hyperpigmentation. HGF has been reported to be upregulated in photoaging-associated hyperpigmentary lesions, together with other dermal fibroblast- and keratinocyte-derived paracrine factors such as basic fibroblast growth factor (bFGF), stem cell factor (SCF), and endothelin-1 (ET-1) [19, 35–38]. On this basis, these growth factors have been widely regarded as melanogenic. Numerous subsequent studies have demonstrated that bFGF, SCF, and ET-1, which are also elevated in UV-mediated hyperpigmented lesions such as solar lentigines, directly stimulate melanogenesis in melanocytes [11, 19, 39–43]. However, despite its association with hyperpigmented lesions, direct functional evidence supporting a melanogenic role for HGF in melanocytes remains limited. Indeed, a study using keratinocyte-specific HGF overexpression in transgenic mice on a C57BL/6J background reported a marked increase in overall pigmentation, with enhanced and altered melanocyte development and distribution—particularly increased dermal melanocyte numbers—and proliferation [44]. This observation, however, does not necessarily imply a direct causative role of HGF in melanin production per cell. Consistent with this observation, most studies on HGF have focused on its roles in melanocyte proliferation and survival or on lesion- and UV-related correlational analyses [45, 46], and no study to date has directly examined its effects on melanogenesis in detail. Thus, our results were unexpected. Contrary to prevailing assumptions, HGF exhibited a clear anti-melanogenic activity. These anti-melanogenic effects of HGF were consistently observed in vivo using topical HGF application in mouse models and ex vivo in human skin explants. Together with the findings from keratinocyte-specific HGF transgenic mice [44], our data suggest that HGF in skin primarily influences melanocyte development and distribution. Importantly, however, HGF itself appears to suppress melanin synthesis in melanocytes rather than promoting it. Considering that HGF is also known for its anti-inflammatory and tissue-repair functions [16], the elevated HGF levels observed in inflammatory skin conditions and PIH may represent a feedback response aimed at limiting inflammation and restoring tissue homeostasis, rather than a direct driver of melanogenesis. Mechanistically, we initially hypothesized that HGF might regulate MITF transcript and protein levels, because ERK, a well-established downstream effector of HGF–c-Met signaling, has been reported to enhance transcriptional activity of CRTC3/CREB in HEK293T cells [29], which in turn could increase MITF transcription. However, HGF neither affected CREB transcriptional activity nor altered MITF mRNA levels in melanocytes in our results. Instead, HGF markedly reduced the nuclear localization of MITF, leading to suppression of MITF transcriptional activity and downregulation of melanogenesis-related gene expression. MITF is a master regulator of both melanocyte survival and pigmentation, and its activity is tightly controlled by post-translational modifications and subcellular localization [47–49]. In melanoma cells, MAPK signaling has been shown to converge on MITF to regulate its nuclear localization and transcriptional activity, in particular, via ERK-mediated phosphorylation of MITF at Ser73 [31]. In the present study, HGF appeared to induce activation of ERK, resulting in phosphorylation of MITF at regulatory serine residues that promote its nuclear export. Notably, although HGF is known to activate MITF-dependent survival signaling, melanocyte viability was preserved while melanogenic activity was suppressed. This dissociation between survival and pigmentation suggests that proliferative signaling can be maintained independently of MITF transcriptional control, for example via HGF-mediated AKT activation, while MITF-mediated melanogenic gene expression is concurrently suppressed. Preservation of melanocyte viability while preventing excessive melanin synthesis is critical for maintaining pigmentary homeostasis in aged or photoaged skin. Consistent with previous studies demonstrating that HGF promotes melanocyte survival and proliferation during development and in adult skin [15, 50], our findings indicate that HGF suppresses excessive melanogenesis while maintaining melanocyte integrity, highlighting its potential utility in preventing skin aging and dyschomia. HGF/c-Met signaling has been extensively studied in the context of cancer progression, where it contributes to epithelial–mesenchymal transition, angiogenesis, invasion, and therapeutic resistance [51, 52]. Our results underscore the context-dependent nature of HGF signaling and emphasize the importance of distinguishing oncogenic signaling in cancer cells from physiological signaling in normal pigment cells [15, 52–54]. Furthermore, our findings should be interpreted within the broader framework of cutaneous pigment homeostasis, in which melanogenesis is regulated by highly integrated environmental, inflammatory, and neuroendocrine signaling networks. Given the established anti-inflammatory and tissue-repair functions of HGF, increased HGF expression observed in hyperpigmented or inflammatory skin lesions may reflect a compensatory response aimed at restoring tissue homeostasis rather than directly promoting pigmentation. In this context, targeted modulation of the HGF signaling axis may provide a therapeutic strategy for hyperpigmentation disorders. In conclusion, our study demonstrates that HGF suppresses melanogenesis by inducing ERK-dependent nuclear export of MITF. These findings challenge the conventional view of HGF as a melanogenic factor and instead identify HGF as a negative regulator of pigment homeostasis. Further elucidation of the molecular mechanisms underlying HGF-mediated modulation of melanocyte function may provide new therapeutic insights into pigmentation disorders associated with skin aging (Fig. 7). Schematic diagram illustrating the regulation of melanogenesis by HGF–ERK–MITF signaling Conclusions Our findings, contrary to the previously held belief that HGF is a melanogenic factor, reveal that HGF is a negative regulator of melanogenesis. Given its effect of promoting melanocyte survival, HGF may be a promising topical preventative strategy for photoaging-related hyperpigmentation without increasing the risk of unwanted melanocyte loss. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors would like to thank Dr. Hyun Ho Han of the Department of Plastic Surgery at Asan Medical Center for providing human skin samples. Abbreviations Hepatocyte growth factor Ultraviolet radiation Post-inflammatory hyperpigmentation Forskolin L-3,4-dihydroxyphenylalanine Cholera toxin 12-O-tetradecanoylphorbol-13-acetate Dulbecco’s Modified Eagle Medium Dulbecco’s phosphate-buffered saline Fetal bovine serum Human Melanocyte Growth Supplement Human Keratinocyte Growth Supplement Antibiotic-Antimycotic Human dermal fibroblasts Normal human primary melanocytes Normal Human epidermal keratinocytes Bovine serum albumin Quantitative reverse transcription polymerase chain reaction Stem cell factor Hematoxylin and Eosin Microphthalmia-associated transcription factor AMP-activated protein kinase Basic fibroblast growth factor Endothelin-1 Hypothalamus pituitary adrenal Melanocortin receptor 1 α-melanocyte-stimulating hormone Author contributions SEC, and YS conceptualized, designed the experiments, and supervised the experiments. JHL, JMY, SEC, and YS determined the methodology. JHL and JMY performed the experiments, visualized, and curated the data. JHL, SEC, and YS wrote the original draft. SEC and YS reviewed and edited the manuscripts. SEC and YS acquired the funding. Funding This study was supported by grants from COSMAX, Inc, (SEC) the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea (2023IP0019) (YS), and the National Research Foundation of Korea (RS-2026-25468538) (YS). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Asan Medical Center, Seoul, Korea (Approval No. 2024-10-171). Human skin tissue was collected with consent from patients undergoing abdominal reduction surgery and used in accordance with the guidelines of the Institutional Review Board of Asan Medical Center (IRB# 2020-0091). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Youngsup Song, Email: ysong@amc.seoul.kr. Sung Eun Chang, Email: cse@amc.seoul.kr. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.